Drug-Eluting Stents Versus Bare-Metal Stents in Large Coronary Artery Revascularization: Systematic Review and Meta-Analysis

Costa, 2019, Does large vessel size justify use of bare-metal stents in primary percutaneous coronary intervention?, Circ Cardiovasc Interv, 12, 10.1161/CIRCINTERVENTIONS.118.007705 Rymer, 2016, Trends in bare-metal stent use in the United States in patients aged ≥65 years (from the CathPCI Registry), Am J Cardiol, 118, 959, 10.1016/j.amjcard.2016.06.061 Morice, 2013, Why are we still using coronary bare-metal stents?, J Am Coll Cardiol, 61, 1122, 10.1016/j.jacc.2012.11.049 Bønaa, 2016, Drug-eluting or bare-metal stents for coronary artery disease, N Engl J Med, 375, 1242, 10.1056/NEJMoa1607991 Colombo, 2017, Should we still have bare-metal stents available in our catheterization laboratory?, J Am Coll Cardiol, 70, 607, 10.1016/j.jacc.2017.05.057 Rudolph, 2014, Surface modification of biodegradable polymers towards better biocompatibility and lower thrombogenicity, PLoS One, 10 Babapulle, 2004, A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents, Lancet, 364, 583, 10.1016/S0140-6736(04)16850-5 James, 2009, Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden, N Engl J Med, 360, 1933, 10.1056/NEJMoa0809902 Kastrati, 2007, Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction, Eur Heart J, 28, 2706, 10.1093/eurheartj/ehm402 Morice, 2002, A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N Engl J Med, 346, 1773, 10.1056/NEJMoa012843 Moses, 2003, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery, N Engl J Med, 349, 1315, 10.1056/NEJMoa035071 Steinberg, 2007, Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (≥3.5 mm) coronary arteries, Am J Cardiol, 99, 599, 10.1016/j.amjcard.2006.09.105 Spaulding, 2007, A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents, N Engl J Med, 356, 989, 10.1056/NEJMoa066633 Stettler, 2007, Outcomes associated with drug-eluting and baremetal stents: a collaborative network meta-analysis, Lancet, 370, 937, 10.1016/S0140-6736(07)61444-5 Stone, 2004, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N Engl J Med, 350, 221, 10.1056/NEJMoa032441 Foley, 1994, Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty, Circulation, 90, 1239, 10.1161/01.CIR.90.3.1239 Elezi, 1998, Vessel size and long-term outcome after coronary stent placement, Circulation, 98, 1875, 10.1161/01.CIR.98.18.1875 Cutlip, 2002, Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials, J Am Coll Cardiol, 40, 2082, 10.1016/S0735-1097(02)02597-4 Bangalore, 2012, Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials, Circulation, 125, 2873, 10.1161/CIRCULATIONAHA.112.097014 Mahmoud, 2018, Safety and efficacy of second-generation drug-eluting stents compared with bare-metal stents: an updated meta-analysis and regression of 9 randomized clinical trials, Clin Cardiol, 41, 151, 10.1002/clc.22855 Chichareon, 2019, Efficacy and safety of stents in ST-segment elevation myocardial infarction, J Am Coll Cardiol, 74, 2572, 10.1016/j.jacc.2019.09.038 Piccolo, 2019, Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials, Lancet, 393, 2503, 10.1016/S0140-6736(19)30474-X Shah, 2018, Efficacy and safety of drug-eluting stents optimized for biocompatibility vs bare-metal stents with a single month of dual antiplatelet therapy: a meta-analysis, JAMA Cardiol, 3, 1050, 10.1001/jamacardio.2018.3551 Geng, 2013, Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials, Catheter Cardiovasc Interv, 81, 1087, 10.1002/ccd.24599 Lee, 2018, The newest generation of drug-eluting stents and beyond, Eur Cardiol, 13, 54, 10.15420/ecr.2018:8:2 Worthley, 2017, First-in-human evaluation of a novel polymerfree drug-filled stent: angiographic, IVUS, OCT, and clinical outcomes from the RevElution study, JACC Cardiovasc Interv, 10, 147, 10.1016/j.jcin.2016.10.020 Schmidt, 2018, Coronary stents: history, design, and construction, J Clin Med, 7, 126, 10.3390/jcm7060126 Kaiser, 2010, Drug-eluting versus bare-metal stents in large coronary arteries, N Engl J Med, 363, 2310, 10.1056/NEJMoa1009406 Higgins, 2003, Measuring inconsistency in metaanalyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Higgins, 2016, A revised tool for assessing risk of bias in randomized trials, Cochrane Database Syst Rev, 10, 29 Grube, 2005, Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I), Am J Cardiol, 96, 79, 10.1016/j.amjcard.2005.03.030 Bulluck, 2016, Hausenloy DJReducing myocardial infarct size: challenges and future opportunities, Heart, 102, 341, 10.1136/heartjnl-2015-307855 Bhatt, 2012, EXAMINATION of new drug-eluting stents—top of the class!, Lancet, 380, 1453, 10.1016/S0140-6736(12)61021-6 Alraies, 2017, Diagnosis and management challenges of in-stent restenosis in coronary arteries, World J Cardiol, 9, 640, 10.4330/wjc.v9.i8.640 Pfisterer, 2006, Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents, J Am Coll Cardiol, 48, 2584, 10.1016/j.jacc.2006.10.026 Stone, 2007, Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents, N Engl J Med, 356, 998, 10.1056/NEJMoa067193 Kastrati, 2007, Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents, N Engl J Med, 356, 1030, 10.1056/NEJMoa067484 Lagerqvist, 2007, Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden, N Engl J Med, 356, 1009, 10.1056/NEJMoa067722 Jensen, 2012, Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with STsegment elevation myocardial infarction, Am J Cardiol, 109, 629, 10.1016/j.amjcard.2011.10.018 Liu, 2017, Comparison of efficacy and safety between first and second generation drug-eluting stents in patients with stable coronary artery disease: a single-center retrospective study, Chin Med J (Engl), 130, 1654, 10.4103/0366-6999.209904 Watanabe, 2019, Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial, JAMA, 321, 2414, 10.1001/jama.2019.8145 Kim, 2020, Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial, JAMA, 323, 2407, 10.1001/jama.2020.7580 Chevalier, 2019, Primary PCI: a drug-eluting stent, what Else?, J Am Coll Cardiol, 74, 2585, 10.1016/j.jacc.2019.09.037 Cox, 2008, Are DES beneficial in large vessels compared to BMS? Data from the TAXUS IV and V randomized clinical trials, J Am Coll Cardiol, 51 Pfisterer, 2008, Long-term benefit–risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET, Eur Heart J, 30, 16, 10.1093/eurheartj/ehn516 Colombo, 2003, Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions, Circulation, 108, 788, 10.1161/01.CIR.0000086926.62288.A6 Bjerking, 2019, Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials, Open Heart, 6, 10.1136/openhrt-2018-000986